These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1071 related articles for article (PubMed ID: 32164626)

  • 1. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
    Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
    Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
    Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET
    J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
    Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Tumor Suppressor BRCA1/2, Cancer Susceptibility and Genome Instability in Gynecological and Mammary Cancers.
    Oubaddou Y; Ben Ali F; Oubaqui FE; Qmichou Z; Bakri Y; Ameziane El Hassani R
    Asian Pac J Cancer Prev; 2023 Sep; 24(9):3139-3153. PubMed ID: 37774066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers.
    Batalini F; Gulhan DC; Mao V; Tran A; Polak M; Xiong N; Tayob N; Tung NM; Winer EP; Mayer EL; Knappskog S; Lønning PE; Matulonis UA; Konstantinopoulos PA; Solit DB; Won H; Eikesdal HP; Park PJ; Wulf GM
    Clin Cancer Res; 2022 Nov; 28(21):4714-4723. PubMed ID: 36048535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
    Lenz L; Neff C; Solimeno C; Cogan ES; Abramson VG; Boughey JC; Falkson C; Goetz MP; Ford JM; Gradishar WJ; Jankowitz RC; Kaklamani VG; Marcom PK; Richardson AL; Storniolo AM; Tung NM; Vinayak S; Hodgson DR; Lai Z; Dearden S; Hennessy BT; Mayer EL; Mills GB; Slavin TP; Gutin A; Connolly RM; Telli ML; Stearns V; Lanchbury JS; Timms KM
    Breast Cancer Res Treat; 2023 Nov; 202(1):191-201. PubMed ID: 37589839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
    Pothuri B
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii22-viii27. PubMed ID: 24131965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
    Tutt A; Tovey H; Cheang MCU; Kernaghan S; Kilburn L; Gazinska P; Owen J; Abraham J; Barrett S; Barrett-Lee P; Brown R; Chan S; Dowsett M; Flanagan JM; Fox L; Grigoriadis A; Gutin A; Harper-Wynne C; Hatton MQ; Hoadley KA; Parikh J; Parker P; Perou CM; Roylance R; Shah V; Shaw A; Smith IE; Timms KM; Wardley AM; Wilson G; Gillett C; Lanchbury JS; Ashworth A; Rahman N; Harries M; Ellis P; Pinder SE; Bliss JM
    Nat Med; 2018 May; 24(5):628-637. PubMed ID: 29713086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
    Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
    Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
    Moschetta M; George A; Kaye SB; Banerjee S
    Ann Oncol; 2016 Aug; 27(8):1449-55. PubMed ID: 27037296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biallelic
    Wineland D; Le AN; Hausler R; Kelly G; Barrett E; Desai H; Wubbenhorst B; Pluta J; Bastian P; Symecko H; D'Andrea K; Doucette A; Gabriel P; Reiss KA; Nayak A; Feldman M; Domchek SM; Nathanson KL; Maxwell KN; ;
    JCO Precis Oncol; 2023 Aug; 7():e2300036. PubMed ID: 37535879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.
    Pradhan M; Risberg BA; Tropé CG; van de Rijn M; Gilks CB; Lee CH
    BMC Cancer; 2010 Sep; 10():493. PubMed ID: 20843305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
    BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
    Tian T; Shan L; Yang W; Zhou X; Shui R
    Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    Škapa P; Dundr P
    Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.